Related Experiment Video

Updated: Mar 24, 2026

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.2K

Ivabradine for the treatment of chronic heart failure

Christine Henri1, Eileen O'Meara1, Simon De Denus1

  • 1a Research Center and Department of Medicine, Montreal Heart Institute , Université de Montréal , Montréal , Québec , Canada.

Expert Review of Cardiovascular Therapy
|March 12, 2016
PubMed

Insights

Lowering heart rate with ivabradine in chronic heart failure patients improves outcomes. This heart rate-lowering drug offers benefits when beta-blockers are insufficient.

Area of Science:

  • Cardiology
  • Pharmacology
  • Heart Failure Management

Background:

  • Lowering heart rate is linked to improved mortality in chronic heart failure with reduced ejection fraction.
  • Achieving target heart rates (≤70 bpm) with beta-blockers alone is often challenging in clinical practice.
  • Current guidelines recommend ivabradine for patients with persistent symptoms and heart rate ≥70 bpm despite optimal therapy.

Purpose of the Study:

  • To evaluate the benefits of combining standard heart failure pharmacotherapy with ivabradine.
  • To assess the impact of ivabradine on prognosis, cardiac structure and function, exercise tolerance, and quality of life.

Main Methods:

  • Review of current pharmacological therapies for chronic heart failure.
  • Evaluation of ivabradine as a selective heart rate-reducing agent.
  • Analysis of clinical data supporting the combination therapy.

Main Results:

  • Ivabradine is a well-tolerated and safe treatment option.
  • The drug effectively reduces heart rate in patients with chronic heart failure.
  • Combination therapy aims to improve patient prognosis and quality of life.

Conclusions:

  • Combining ivabradine with standard heart failure medications offers a valuable therapeutic strategy.
  • This approach addresses unmet needs in patients with persistent symptoms and elevated heart rates.
  • Ivabradine contributes to improved left ventricular function and exercise capacity.

Keywords:
Ivabradinebeta-blockersexercise toleranceheart failureheart rate reductionleft ventricular functionquality of life

More Related Videos

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

9.4K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
512
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
537
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K